Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation in pathologic myopia

Faik Gelisken*, Werner Inhoffen, Alexander Hermann, Salvatore Grisanti, Karl Ulrich Bartz-Schmidt

*Corresponding author for this work
21 Citations (Scopus)


Background: To report long-term functional and morphological outcome of verteporfin photodynamic therapy (PDT) for classic extrafoveal choroidal neovascularisation (CNV) secondary to pathologic myopia. Methods: This retrospective case series included three eyes of three consecutive patients with classic extrafoveal CNV secondary to pathologic myopia, who underwent PDT at a tertiary retinal referral centre. Change in visual acuity and fluorescein leakage was the main outcome criteria. Results: The patients were followed up an average of 36 months (33-40 months). In all eyes increase of visual acuity (one eye 1 ETDRS line, two eyes 2 ETDRS line) and no fluorescein leakage of the CNV were seen. Conclusions: PDT can achieve long-term improvement of the visual acuity and morphological stability in selected cases with classic extrafoveal CNV in pathologic myopia. Large scale randomised studies are warranted for assessment of the benefit of PDT in such eyes.

Original languageEnglish
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Issue number11
Pages (from-to)926-930
Number of pages5
Publication statusPublished - 11.2004

Research Areas and Centers

  • Research Area: Luebeck Integrated Oncology Network (LION)


Dive into the research topics of 'Verteporfin photodynamic therapy for extrafoveal choroidal neovascularisation in pathologic myopia'. Together they form a unique fingerprint.

Cite this